It was shown that Tacrolimus (TAC) can suppress inflammation and immune response involved in liver ischemic reperfusion injury (IRI) (Kristo I., Transpl Int. 2011). The aim: We hypothesize that back-table arterial and portal liver perfusion with TAC can influence the incidence and severity of EAD. A prospective randomized study was conducted (ClinicalTrials.gov Identifier: NCT01887171). Materials and methods: Including criteria: 1 st liver transplantation from DBD donor with sequential portal-arterial reperfusion. At back-table portal vein and hepatic artery were perfused each by 500 ml of HTK solution containing 20 ng/ml TAC during 10-15 min followed by portal flushing with 200 ml 5% solution of Albumin containing 20 ng/ml TAC and by resting of liver in effluent. No Tac was added in the control group. Primary Outcome: EAD (Olthoff KM, et al. Liver Transpl. 2010) and severe EAD (P.R. Salvalaggio, et al. Transpl. Proceedings, 2012). Results: No difference was found between groups (main vs. control) in terms of MELD (16 vs. 16), steatosis (10 vs. 10%), ballooning (45 vs. 40%) of liver grafts, recipient's age (50 vs. 50y), warm ischemia time (50 vs. 50 min) and total ischemia time (482.5 vs. 485.0 min). Median donor age was higher in the main group (44.5 vs. 39.0y). The overall rate of EAD was 27.9%. EAD rate was significantly lower in the main group (6/43 vs. 18/43; p=0.003). The rate of moderate-to-severe EAD was lower in the main group (1/43 vs. 10/43; p=0.009). The median level of AST and ALT 24 h after reperfusion were significantly lower in the intervention group (1004 vs. 1596; p=0.03 and 449 vs. 759; p=0.057). Conclusion: Portal and arterial back-table liver perfusion by HTK solution with Tacrolimus may contribute to lower EAD incidence and severity.
INTRODUCTION INTRODUCTION
Liver transplantation (LT) has dramatically changed the prognosis for patients with end-stage chronic liver diseases and certain neoplasms. Success of the surgery, however, is still complicated by the gap between the number of patients on waiting lists and available donors despite the introduction of SPLIT liver transplantation and live donor transplantation. This gap leads to 10 -20% mortality on waiting lists and the need for use of extended criteria donor (ECD) organs. However, the use of extended criteria donors is associated with early allograft dysfunction (EAD) caused by ischemia reperfusion injury (IRI) (1) .
Salvalaggio et al. demonstrated that severe EAD is accompanied with significantly lower one-year survival rate of both the graft (54.6% vs. 91.8%, р< 0.001) and the patient (71.7% vs. 94%, р< 0.001) as compared to moderate EAD (2) . A number of phenotypic risk factors are associated with EAD incidence. Among them: donor older age, serum Sodium level, hepatic steatosis, hypotension, prolonged cold and warm ischemia time, mechanical ventilation > 5 days, deceased cardiac donor and split or reduced graft (3) . MELD score and urgency of transplantation -are well-known recipient's risk factors (4) .
As far as most EAD risk factors are impossible (donor age, MELD, urgency, hepatic steatosis, need for vasopressors) or difficult to influence on (cold and warm ischemic time, damage during conditioning), and taking in consideration that cold storage is currently a part of the clinical routine in LT, reduction of total and warm ischemia time and pharmacological liver protection remain the basic strategies of EAD prevention. Due to its availability and reproducibility, pharmacological liver protection is one of the most studied practices of IRI attenuation and EAD prevention. The most available points of administration of pharmacological liver protection are donor conditioning and procurement, back-table flushing and rinse. In this regard, the effects of methylprednisolone (6) , sevoflurane (7), nitrogen oxide (8), acetylcysteine, specific P-selectin blocker, etc. were studied (9) .
Experimental data point to a possible role of calcineurin inhibitor Tacrolimus in IRI attenuation and liver protection during LT (10, 11, 12) . Tacrolimus was shown to be able to inhibit inflammation and immune response in the transplanted liver at the genomic level; the available data on protective function of calcineurin inhibitors in cardiac IRI indicate organ-nonspecific possible mechanism of action (13, 14) . However, clinical efficacy of Tacrolimus for the liver protection remains doubtful due to insufficient power of known studies, patient characteristics and mode of drug administration (13 and 10 patients in a group, mean level of hepatosis 1%, relatively short median total ischemic time, administration only in portal vein or portal and arterial flushing at the time of caval anastomosis formation, i.e. in situ) (15) .
In that context we designed a clinical study and hypothesized that back-table portal and arterial liver graft flushing with histidine-tryptophan-ketoglutarate (HTK) solution containing tacrolimus and subsequent portal rinse of donor liver with albumin solution containing tacrolimus, that makes a relatively prolonged exposure of tacrolimus, can reduce the incidence and/or severity of EAD.
AIM AIM
To investigate whether back-table portal and arterial flushing with HTK and rinse with albumin solution both containing tacrolimus can influence the incidence and severity of EAD.
Primary end-points: incidence and severity of EAD. Secondary end-points: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels during the first 24 and 48 hours after LT, severity of IRI according to liver biopsy 2 hours after portal reperfusion, markers of inflammatory response tested in blood samples of hepatiс veins after reperfusion.
MATERIALS AND METHODS MATERIALS AND METHODS
A prospective randomized single-center doubleblind study was conducted (Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing with Tacrolimus; registered with clinicaltrials.gov, NCT01887171). Inclusion criteria: donor age 15 -65 years, macrovesicular steatosis < 40%, serum sodium < 165 mmol/L, mechanical ventillation < 11 days, cold ischemia time < 13 hours, AST and ALT < 200 IU/L, total bilirubin < 30 μmol/L; from the recipient's side: age 18 -69 years; transplantation technique with resection of the inferior vena cava, sequential portal and arterial reperfusion and no bypass. Exclusion criteria: LT from a living-related donor, reduced/split graft, LT for fulminant liver failure and re-LT for primary non-function. Calculation of the group size was performed considering the power of the study 0.80, type I error probability α= 0.05 and analysis of results of 166 LTs performed before the study. Assuming that utilization of portal and arterial perfusion of liver graft with HTK solution containing tacrolimus causes reduction of EAD incidence from 30% to 5%, each study group should include 35 -41 patients (16) . On the grounds of power calculation, 86 patients were included into the study (43 per each group). Randomization was achieved by opening the envelopes before the back-table.
All deceased donors were administered methylprednisolone in the dose of 1.0 g intravenously before the beginning of multiple organ retrieval. At the stage of donor operation liver biopsy was performed for subsequent assessment of the severity of hepatic steatosis and balloon dystrophy.
During the back-table the portal vein and common hepatic artery were cannulated. Portal vein flushing was performed under the gravity pressure of 40 -60 cm with 500 ml of HTK solution containing 20 ng/mL of tacrolimus. After that hepatic artery flushing was performed with 500 ml of the same solution under the pressure of 40 -50 mm Hg. Then portal rinse was achieved with 200 mL of 5% Albumin solution containing 20 ng/mL of tacrolimus. Donor liver was left in the basin and, in case the expected time to implantation exceeded 30 min, was cooled to 2 -6°С after packing into sterile plastic bags. In the control group, no tacrolimus was added to the HTK solution. After the end of flushing and rinsing procedure, the effluent from the basin of 16 random cases of the main group was sampled for tacrolimus concentration assessment.
Blood samples from hepatic veins at baseline (immediately after portal reperfusion), one hour after the portal reperfusion, peripheral blood samples 24 and 72 hours after the surgery were used for determination of interleukins (ILs) 2, 6, 8, 17, 23 levels by multiplex immunoassay.
Two hours after portal reperfusion, liver biopsy was performed in order to assess IRI severity. The biopsy sample was placed into buffered formalin and shipped into the morphological laboratory. The protocol for blood and biopsy sampling is presented in table 1.
Multiplex analysis was performed using Luminex 200 based on хМАР technology by Luminex (USA) with the help of magnetic particles "Milliplex Mag" and panels included into commercial test-systems MILLIPLEX (Millipore, USA). Tacrloimus concentration was determined by instrumental method using the Architect i2000SR analyzer.
EAD was defined according to Olthoff KM et. al. criteria: (1) total bilirubin >170 μmol/L on the 7 th postoperative day, or (2) МНО > 1.6 on the 7 th postoperative day, or (3) aminotransferases level (AST or ALT) > 2000 u/L during the first postoperative week (17) . Severe EAD was defined according to Salvalaggio et al. and divided into mild (AST and ALT < 3000 u/L) and moderate-to-severe (AST and ALT > 3000 u/L, МНО>1.6 and total bilirubin >170 μmol/L) (2) .
Statistical analysis was performed using STATISTICA 8 package for Windows and SPSS 22 for Macintosh. Mean values are shown as median (25%-75%). Literature search was performed in Pubmed (NLM) electronic database using Endnote®Web software package for Macintosh.
This study was conducted in accordance with the protocol and the principles of the Declaration of Helsinki. The protocol was approved by the Institutional Research Board of the center in accordance with local regulations.
Patient characteristics are presented in table 2. The groups were comparable by MELD score, recipient age, total and warm ischemic time of the, steatosis and balloon dystrophy severity. Donor age was significantly older in the control group which could have been taken into consideration in case of alternative hypothesis disconfirmation. As far as inclusion criteria allowed only mild bilirubin and AST and ALT elevation in donor, no donors with liver dysfunction exceeding these criteria were included to the study.
RESULTS RESULTS

Clinical efficacy
Median EAD incidence amounted to 27.9% (24/86 Primary non-function of the graft developed in one case in each group (Fisher exact; p = 1). Renal failure incidence requiring renal replacement therapy in early postoperative period did not differ in the main, 9/43, and control, 6/43, groups (χ 2 =0.7; p=0.5). Septic complications incidence showed no significant differences in the studied groups, as well, and accounted to 20% (9/43) in the main group and 16.2% (7/43) in the control group (χ 2 =0.31; p=0.7). Hospital mortality amounted to 4.6%(2/43) in the main group and was slightly lower than that in the control group 6.9% (3/43), (Fisher exact; p =1). The fatal cases on days 28 and 60 in the main group were caused by PNF of the graft in the first case and by sepsis in both cases (MRSA + Acinetobacter and Enterococcus + Acinetobacter). The reason of the fatal cases on days 7, 23 and 65 in the control group was PNF of the graft (n=1), acute herpetic hepatitis (n=1) and sepsis (n=1; Enterococcus + Acinetobacter).
IRI
Morphological study for IRI evaluation was performed in 23 cases in the control group and in 24 cases in the main group. Severe IRI incidence (necrosis in the pericentral and the 2 nd zone > 30%, apoptosis 3 -5%) amounted to 26% (6/23) in the control group and was significantly greater than that in the main group, 4,1% (1/24), (Fisher exact; p=0.04). Moderate-to-severe IRI demonstrated statistically less significant difference between the groups (necrosis >15%, apoptosis 1.5 -5%).
Tacrolimus effluent concentration
Median TAC concentration in effluent in which the donor liver was submerged after the end of the perfusion amounted to 6.6 (5.3;14.7) ng/mL. 
Serologic markers
Recent data (4) suggests about involvement of cytokines into the IRI mechanism and considers them as potential surrogate markers of tacrolimus perfusion efficacy/inefficacy.
In our study the difference in the IL-17 level between hepatic vein blood samples measured immediately after portal reperfusion and one hour after it was significantly less in the group of patients receiving arterial-portal flushing with tacrolimus and portal rinse during the back-table ( fig. 1) .
In the tacrolimus group a statistically significant reduction of the IL-6 concentration 24 hours after the surgery was noted, 2.2 (0.1;20.9) ng/mL, as compared to the control group, 37.6 (6.1;56.2) ng/mL, р=0.03; ( fig. 2) and the tendency to reduction of the IL-2 concentration 24 hours after the surgery, 0.83(0.1;14.9) ng/mL, as compared to the IL-2 level, 42.01 (18.9;50.6) ng/mL, in the group without tacrolimus (р=0.07; fig. 3 ). Also, a trend toward reduction of the IL-23 level was noted in the hepatic veins sample 1 hour after reperfusion in the main group as compared to the IL-23 level in the group without tacrolimus (р=0.05; fig. 4 ).
DISCUSSION DISCUSSION
Pharmacological liver protection is theoretically justified by necessity to attenuate IRI as the cause of EAD in LT. Bussutil et al. suggested IRI mechanism with Despite the promising data, the results of these studies could not be interpreted as reliable for introduction into clinical practice due to high probability of a random error. Study groups in both cases (10 and 13 patients) were insufficient for drawing clinical conclusions. Apart from design drawbacks, these studies had also methodic peculiarities not matching the liver protection idea of the method. Thus, in the work of Kristo I the pressure of 147 mm Hg was used for portal vein perfusion, which can cause damage to endothelium of liver sinusoids and may lead to hepatic failure (24) . Finally, in both studies donor organs suffered lower risk of IRI and subsequent EAD due to insignificant hepatic steatosis (1%, Kristo I) and small median total ischemic time (384 min, Peter SD).
20 ng/mL tacrolimus concentration in our study was chosen on the grounds of safety data in previous studies, as well as the range of maintained plasma concentrations recommended by manufacturer (25).
The difference of our method in convenient way of back-table flushing when the liver is cooled in the basin with ice; use of portal vein perfusion pressure (40 -60 cm of gravity) excludes damage and activation of endothelial cells of sinusoids; hepatic artery flushing under the pressure of 40 -50 cm Hg; presence of tacrolimus in the rinsing solution (albumin).
Portal and arterial perfusion of liver graft with the HTK solution and tacrolimus in our study resulted in reduced incidence of all EADs, particularly moderate-tosevere EAD according to the criteria of P.R. Salvalaggio (2.3% vs. 23.2%), which was not demonstrated before.
The severity of hepatic cells necrosis in postreperfusion liver biopsy sample is a known sign of preservation and reperfusion injury and predictor of EAD (26) . The morphological proof of this method's effect was reduced severe IRI incidence in postreperfusion live biopsy samples, which was not noted before in the studies of efficacy of pre-reperfusion flushing with tacrolimus.
Liver injury in the result of IRI is a typical example of damage-associated molecular patterns (DAMP) effect. DAMPs are their own tissues disintegration products possessing antigen-specific properties; they play the main role in induction of immune and inflammatory response at the early stage of organ failure, before the onset of infection. The modern model of DAMPmediated liver injury is presented below: necrotizing hepatic cells form several DAMP types, such as nuclear non-histone proteins (HMGB1), heat-shock proteins, mitochondrial DNA and cyclophilin А. Extracellular HMGB1 binds with several receptors, such as TLR2, TLR4, TLR9. Responding to TLR stimulation, macrophages and endothelial cells became activate. TLR-4 receptor-activated macrophages release IL-23. IL-23 stimulates γδ-T cells to produce IL-17. IL-17 recruits neutrophils into liver (27) . It is also known that EAD incidence is associated with a certain profile of inflammatory cytokines in peripheral blood of both donors and recipients (28) . In this regard, the results of this work are remarkable due to not only the change of IL-2, 6 levels 24 hours after reperfusion in peripheral blood of patients of the main group, but also IL-17 and IL-23 levels in liver outflow blood one hour after portal reperfusion, which explains the possible mechanism of action of portal and arterial perfusion with tacrolimus.
We didn't measure the dependence of IRI severity from tacrolimus concentration in effluent, that could be a significant additional research evidence.
The results in some part are the consequence of study circumstances -we don't accept marginal grafts in our Center (reflection of that is the average steatosis), median ischemia time only 8 hours and preservation solution -HTK. It is not excluded that use of marginal liver grafts, UW solution and different ischemia time could influence the study results.
The limitation of this study is an absence of the method's effect on hospital mortality. Despite this, the study group of patients is a part of a cohort (307 patients at the time of writing this article) where patients with EAD suffered mortality risk 2.5 times higher than that in patients without EAD (p=0.012; 95% CI1.2 -5.2). On the other hand, hospital mortality in the cohort of 342 patients in our center amounts to 6.4%, which does not allow assess the method's effect on mortality in the group of 43 patients from the statistical point of view. The economic effect of EAD prevention is important as well, as the cost of treatment of patients with EAD is known to exceed that of patients without EAD by several times.
Thus, use of HTK and albumin solutions with tacrolimus infusion into the portal vein and hepatic artery during the back-table is an effective method to reduce IRI, incidence and severity of EAD in grafts with medium preservation time and standard accepted steatosis level.
